Find policies, billing codes, payers, states, and providers
CPT 81411: Genetic Duplication/Deletion Panel for Aortic Disease
CPT code 81411 is a molecular pathology panel for detecting genetic duplications and deletions across at least four genes implicated in aortic dysfunction or dilation. This multi-gene copy number assessment supports diagnosis and management of heritable aortopathies—conditions with important implications for surgical planning, surveillance, and family screening—and is increasingly relevant as genetic testing becomes integrated into cardiovascular care pathways.
Key payers in the national analysis include Aetna, Blue Cross Blue Shield, Cigna Health, United Healthcare, and Medicare. Coverage and billing practices for panel-based molecular tests vary across commercial and public payers, affecting prior authorization, documentation requirements, and coding bundling policies.
Readers will find an overview of the clinical context for using 81411, how it relates to other molecular pathology levels (for example, single-gene and higher-complexity procedures), and the typical sites of service where testing occurs. The publication summarizes payer coverage patterns and common administrative considerations such as allowed service settings and typical claim handling (Data not available in the input). The content also highlights associated clinical indications for testing and lists closely related molecular pathology codes for reference. This summary provides clinicians, laboratory administrators, and billing staff with a concise national perspective on using CPT code 81411 in molecular genetic evaluation of aortic disease.
Customize your policy alerts
Sign up for cpt 81411 policy alerts
Get alerted when payer policies referencing 81411 are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 81411 describes a laboratory molecular pathology panel that evaluates a patient specimen for genetic duplications and deletions involving at least four genes that are listed in the code descriptor and that may relate to aortic dysfunction or dilation. The service is a molecular genetic test focusing on copy number variants across multiple genes relevant to aortic disease.
Service type: Laboratory molecular pathology panel (genetic testing for copy number variants)
Typical site of service: Clinical laboratory or hospital laboratory with molecular diagnostics capability, with specimens collected in outpatient clinics, specialty genetics clinics, or inpatient settings as clinically indicated.
National Reimbursement Benchmarks
National commercial rates for CPT 81411 cluster around BUCA’s average commercial benchmark of $1,347.20, with Blue Cross Blue Shield and Cigna above that midpoint and UnitedHealth Group and Aetna lower on average. Blue Cross Blue Shield shows the highest median ($1,318.10) and a very large upper tail (max $8,312.30), while Aetna’s distribution centers lower (median $728.00) with a zero minimum noted in its inputs.
Dispersion measured by the interquartile spread (P75 minus P25) is widest for Cigna and Blue Cross Blue Shield at $1,037.90 and $502.00 respectively, indicating greater variability in contracted commercial payments; UnitedHealth Group is intermediate with a spread of $783.10. Aetna has the tightest IQR at $414.50, suggesting relatively constrained variation among its middle 50% of rates.